Literature DB >> 19430537

Targeting Innate Immunity for CV Benefit.

Kathryn J Moore1, Mason W Freeman.   

Abstract

The initiation and progression of vascular inflammation are driven by the retention of cholesterol in the artery wall, where its modification by oxidation and/or enzymes triggers the innate immune host response. Although previously considered a broad, primitive defense mechanism against invading pathogens, it has become clear that pattern recognition receptors of the innate immune system can cooperate to precisely regulate signaling pathways essential for the proper initiation of both innate and acquired immunity. Recent evidence suggests that these pattern recognition receptors may orchestrate the host response to modified endogenous ligands involved in sterile chronic inflammatory syndromes, including atherosclerosis. In this review we will summarize the current understanding of innate immune receptors and the putative ligands that regulate the numerous responses that promote this disease, including monocyte recruitment, macrophage cholesterol uptake, and pro-inflammatory signaling cascades. Specific emphasis will be placed on the potential of these innate immune targets for therapeutic interventions to retard the progression of atherosclerosis or to induce its regression.

Entities:  

Year:  2008        PMID: 19430537      PMCID: PMC2678718          DOI: 10.1016/j.ddstr.2008.05.007

Source DB:  PubMed          Journal:  Drug Discov Today Ther Strateg        ISSN: 1740-6773


  54 in total

Review 1.  Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity.

Authors:  D Steinberg; S Parthasarathy; T E Carew; J C Khoo; J L Witztum
Journal:  N Engl J Med       Date:  1989-04-06       Impact factor: 91.245

2.  Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques.

Authors:  Frank Tacke; David Alvarez; Theodore J Kaplan; Claudia Jakubzick; Rainer Spanbroek; Jaime Llodra; Alexandre Garin; Jianhua Liu; Matthias Mack; Nico van Rooijen; Sergio A Lira; Andreas J Habenicht; Gwendalyn J Randolph
Journal:  J Clin Invest       Date:  2007-01       Impact factor: 14.808

3.  Toll-like receptor 4-dependent and -independent cytokine secretion induced by minimally oxidized low-density lipoprotein in macrophages.

Authors:  Yury I Miller; Suganya Viriyakosol; Dorothy S Worrall; Agnès Boullier; Susan Butler; Joseph L Witztum
Journal:  Arterioscler Thromb Vasc Biol       Date:  2005-02-17       Impact factor: 8.311

4.  Role of macrophage scavenger receptors in diet-induced atherosclerosis in mice.

Authors:  H Sakaguchi; M Takeya; H Suzuki; H Hakamata; T Kodama; S Horiuchi; S Gordon; L J van der Laan; G Kraal; S Ishibashi; N Kitamura; K Takahashi
Journal:  Lab Invest       Date:  1998-04       Impact factor: 5.662

5.  Continued inhibition of atherosclerotic lesion development in long term Western diet fed CD36o /apoEo mice .

Authors:  Ella Guy; Sai Kuchibhotla; Roy Silverstein; Maria Febbraio
Journal:  Atherosclerosis       Date:  2006-08-17       Impact factor: 5.162

Review 6.  The immune response in atherosclerosis: a double-edged sword.

Authors:  Göran K Hansson; Peter Libby
Journal:  Nat Rev Immunol       Date:  2006-06-16       Impact factor: 53.106

7.  Targeted disruption of the scavenger receptor and chemokine CXCL16 accelerates atherosclerosis.

Authors:  Ara M Aslanian; Israel F Charo
Journal:  Circulation       Date:  2006-07-31       Impact factor: 29.690

8.  Effect of torcetrapib on the progression of coronary atherosclerosis.

Authors:  Steven E Nissen; Jean-Claude Tardif; Stephen J Nicholls; James H Revkin; Charles L Shear; William T Duggan; Witold Ruzyllo; William B Bachinsky; Gabriel P Lasala; Gregory P Lasala; E Murat Tuzcu
Journal:  N Engl J Med       Date:  2007-03-26       Impact factor: 91.245

9.  EP 80317, a ligand of the CD36 scavenger receptor, protects apolipoprotein E-deficient mice from developing atherosclerotic lesions.

Authors:  Sylvie Marleau; Diala Harb; Kim Bujold; Roberta Avallone; Khadija Iken; Yanfei Wang; Annie Demers; Martin G Sirois; Maria Febbraio; Roy L Silverstein; André Tremblay; Huy Ong
Journal:  FASEB J       Date:  2005-08-25       Impact factor: 5.191

10.  Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial.

Authors:  Michiel L Bots; Frank L Visseren; Gregory W Evans; Ward A Riley; James H Revkin; Charles H Tegeler; Charles L Shear; William T Duggan; Ralph M Vicari; Diederick E Grobbee; John J Kastelein
Journal:  Lancet       Date:  2007-07-14       Impact factor: 79.321

View more
  1 in total

1.  High-density lipoprotein suppresses the type I interferon response, a family of potent antiviral immunoregulators, in macrophages challenged with lipopolysaccharide.

Authors:  Masashi Suzuki; David K Pritchard; Lev Becker; Andrew N Hoofnagle; Natsuko Tanimura; Theo K Bammler; Richard P Beyer; Roger Bumgarner; Tomas Vaisar; Maria C de Beer; Frederick C de Beer; Kensuke Miyake; John F Oram; Jay W Heinecke
Journal:  Circulation       Date:  2010-10-25       Impact factor: 29.690

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.